0
0

Chapter 19. Trazodone and Nefazodone

Robert N. Golden, M.D.; Karon Dawkins, M.D.; Linda Nicholas, M.D.
DOI: 10.1176/appi.books.9781585623860.412390

Sections

Excerpt

Trazodone was among the earliest "second generation" antidepressants to become available for clinical use in the United States in the early 1980s. Its side-effect profile and potential toxicity were considerably different from and, in many instances preferable to, those of the original antidepressants (i.e., the monoamine oxidase inhibitors [MAOIs] and tricyclic antidepressants [TCAs]). Several years later, its pharmacological "cousin," nefazodone, joined the growing armamentarium of effective antidepressant medications.

Your session has timed out. Please sign back in to continue.
Sign In Your Session has timed out. Please sign back in to continue.
Sign In to Access Full Content
 
Username
Password
Sign in via Athens (What is this?)
Athens is a service for single sign-on which enables access to all of an institution's subscriptions on- or off-site.
Not a subscriber?

Subscribe Now/Learn More

PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing PsychiatryOnline@psych.org or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

FIGURE 19–1. Chemical structure of trazodone.

FIGURE 19–2. Chemical structure of nefazodone.

References

Abernethy DR, Barbey JT, Franc J, et al: Loratadine and terfenadine interaction with nefazodone: both antihistamines are associated with QTc prolongation. Clin Pharmacol Ther 69:96–103, 2001
[PubMed]
 
Ansseau M, Darimont P, Lecoq A, et al: Controlled comparison of nefazodone and amitriptyline in major depressive inpatients. Psychopharmacology (Berl) 115:254–260, 1994
[PubMed]
 
Anton SF, Robinson DS, Roberts DL, et al: Long-term treatment of depression with nefazodone. Psychopharmacol Bull 30:165–169, 1994
[PubMed]
 
Aranda-Michel J, Koehler A, Bejarano PA, et al: Nefazodone-induced liver failure: report of three cases. Ann Intern Med 130:285–288, 1999
[PubMed]
 
Ayd FJ Jr: Pharmacology update: which antidepressant to choose, II: the overdose factor. Psychiatric Annals 14:212–214, 1984
 
Baldwin DS, Hawley CJ, Abed RT, et al: A multicenter double-blind comparison of nefazodone and paroxetine in the treatment of outpatients with moderate-to-severe depression. J Clin Psychiatry 57 (suppl 2):46–52, 1996
 
Baldwin DS, Hawley CJ, Mellors K, et al: A randomized, double-blind controlled comparison of nefazodone and paroxetine in the treatment of depression: safety, tolerability and efficacy in continuation phase treatment. J Psychopharmacol 15:161–165, 2001
[PubMed]
 
Barbhaiya RJ, Sukla UA, Matarakam CS, et al: Single- and multiple-dose pharmacokinetics of nefazodone in patients with hepatic cirrhosis. Clin Pharmacol Ther 58:390–398, 1995
[PubMed]
 
Bergeron L, Boule M, Perreault S: Serotonin toxicity associated with concomitant use of linezolid. Ann Pharmacother 39:956–961, 2005
[PubMed]
 
Benson BE, Mathiason M, Dahl B, et al: Toxicities and outcomes associated with nefazodone poisoning: an analysis of 1,338 exposures. Am J Emerg Med 18:587–592, 2000
[PubMed]
 
Blier P, de Montigny C, Chaput Y: A role for the serotonin system in the mechanism of action of antidepressant treatments: preclinical evidence. J Clin Psychiatry 51 (suppl 4):14–20, 1990
 
Bodner RA, Lynch T, Lewis L, et al: Serotonin syndrome. Neurology 45:219–223, 1995
[PubMed]
 
Bolden-Watson C, Richelson E: Blockade by newly developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci 52:1023–1029, 1993
[PubMed]
 
Brodie-Meijer CC, Diemont WL, Buijs PJ: Nefazodone-induced clitoral priapism. Int Clin Psychopharmacol 14:257–258, 1999
[PubMed]
 
Bystritsky A, Rosen R, Suri R, et al: Pilot open-label study of nefazodone in panic disorder. Depress Anxiety 10:137–139, 1999
[PubMed]
 
Caccia S, Ballabio M, Fanelli R, et al: Determination of plasma and brain concentrations of trazodone and its metabolite, 1-m-chlorophenylpiperazine, by gas-liquid chromatography. J Chromatogr 210:311–318, 1981
[PubMed]
 
Ciraulo DA, Knapp C, Rotrosen J, et al: Nefazodone treatment of cocaine dependence with comorbid depressive symptoms. Addiction 100 (suppl 1):23–31, 2005
 
Clark NA, Alexander B: Increased rate of trazodone prescribing with bupropion and selective serotonin reuptake inhibitors versus tricyclic antidepressants. Ann Pharmacother 34:1007–1012, 2000
[PubMed]
 
Clayton AH, Pradko JF, Croft HA, et al: Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry 63:357–366, 2002
[PubMed]
 
Condren CM, Cooney C: Use of drugs by old age psychiatrists in the treatment of psychotic and behavioural symptoms in patients with dementia. Aging Ment Health 5:235–241, 2001
[PubMed]
 
Costabile RA, Spevak M: Oral trazodone is not effective therapy for erectile dysfunction: a double-blind, placebo-controlled trial. J Urol 161:1819–1822, 1999
[PubMed]
 
Cunningham LA, Borison RL, Carman JS, et al: A comparison of venlafaxine, trazodone, and placebo in major depression. J Clin Psychopharmacol 14:99–106, 1994
[PubMed]
 
de Meester A, Carbutti G, Gabriel L, et al: Fatal overdose with trazodone: case report and literature review. Acta Clin Belg 56:258–261, 2001
 
DeVane CL, Grothe DR, Smith SL: Pharmacology of antidepressants: focus on nefazodone. J Clin Psychiatry 63 (suppl 1):10–17, 2002
 
DeWit S, Cremers L, Hirsch D, et al: Efficacy and safety of trazodone versus clorazepate in the treatment of HIV-positive subjects with adjustment disorders: a pilot study. J Int Med Res 27:223–232, 1999
 
Eison AS, Eison MS, Torrente JR, et al: Nefazodone: preclinical pharmacology of a new antidepressant. Psychopharmacol Bull 26:311–315, 1990
[PubMed]
 
Elliot AJ, Russo J, Bergam K, et al: Antidepressant efficacy in HIV-seropositive outpatients with depressive disorder: an open trial of nefazodone. J Clin Psychiatry 60:226–231, 1999
 
Feiger A, Kiev A, Shriastava RK, et al: Nefazodone versus sertraline in outpatients with major depression: focus on efficacy, tolerability, and effects on sexual function and satisfaction. J Clin Psychiatry 57 (suppl 2):53–62, 1996
 
Feiger AD, Bielski RJ, Bremner J, et al: Double-blind, placebo substitution study of nefazodone in the prevention of relapse during continuation treatment of outpatients with major depression. Int Clin Psychopharmacol 14:19–28, 1999
[PubMed]
 
Feighner J, Targum SD, Bennett ME, et al: A double-blind, placebo-controlled trial of nefazodone in the treatment of patients hospitalized for major depression. J Clin Psychiatry 59:246–253, 1998
[PubMed]
 
Ferguson JM, Shrivastava RK, Stahl SM, et al: Reemergence of sexual dysfunction in patients with major depressive disorder: double-blind comparison of nefazodone and sertraline. J Clin Psychiatry 62:24–29, 2001
[PubMed]
 
Fontaine R: Novel serotonergic mechanisms and clinical experience with nefazodone. Clin Neuropharmacol 16 (suppl 3): S45–S50, 1993
 
Gamble DE, Peterson LG: Trazodone overdose: four years of experience from voluntary reports. J Clin Psychiatry 47:544–546, 1986
[PubMed]
 
Gatrell N: Increased libido in women receiving trazodone. Am J Psychiatry 143:781–782, 1986
 
Georgotas A, Forsell TL, Mann JJ, et al: Trazodone hydrochloride: a wide spectrum antidepressant with a unique pharmacological profile. Pharmacotherapy 2:255–265, 1982
[PubMed]
 
Gerner RH: Geriatric depression and treatment with trazodone. Psychopathology 20:82–91, 1987
[PubMed]
 
Goldberg RJ, Huk M: Serotonin syndrome from trazodone and buspirone (letter). Psychosomatics 33:235–236, 1992
[PubMed]
 
Goodnick PJ, Jorge CM: Treatment of chronic fatigue syndrome with nefazodone. Am J Psychiatry 156:797–798, 1999
[PubMed]
 
Greene DS, Barbhaiya RH: Clinical pharmacokinetics of nefazodone. Clin Pharmacokinet 33:260–275, 1997
[PubMed]
 
Haria M, Fitton A, McTavish D: Trazodone: a review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders. Drugs Aging 4:331–335, 1994
[PubMed]
 
Hedges DW, Reimherr FW, Strong RE, et al: An open trial of nefazodone in adult patients with generalized anxiety disorder. Psychopharmacol Bull 32:671–676, 1996
[PubMed]
 
Hidalgo R, Hertzberg MA, Mellman T, et al: Nefazodone in post-traumatic stress disorder: results from six open-label trials. Int Clin Psychopharmacol 14:61–68, 1999
[PubMed]
 
Horton JC, Trobe JD: Akinetopsia from nefazodone toxicity. Am J Ophthalmol 28:530–531, 1999
 
Hudson JI, Pope HG Jr, Keck PE Jr, et al: Treatment of bulimia nervosa with trazodone: short-term response and long-term follow-up. Clin Neuropharmacol 12 (suppl 1):38–46, 1989
 
Hyttel J: Citalopram—pharmacologic profile of a specific serotonin uptake inhibitor with antidepressant activity. Prog Neuropsychopharmacol Biol Psychiatry 6:277–295, 1982
[PubMed]
 
Janowsky D, Curtis G, Zisook S, et al: Ventricular arrhythmias possibly aggravated by trazodone. Am J Psychiatry 140:796–797, 1983
[PubMed]
 
Jeffries JJ, Al-Jeshi A: Nefazodone-induced mania. Can J Psychiatry 40:218, 1995
[PubMed]
 
Keller MB, McCullough JP, Klein DN, et al: A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med 342:1462–1470, 2000
[PubMed]
 
Klein HE, Muller N: Trazodone in endogenous depressed patients: a negative report and a critical evaluation of the pertaining literature. Prog Neuropsychopharmacol Biol Psychiatry 9:173–186, 1985
[PubMed]
 
Kranzler HR, Modesto-Lowe V, Van Kirk J: Naltrexone vs nefazodone for treatment of alcohol dependence: a placebo controlled trial. Neuropsychopharmacology 22:493–503, 2000
[PubMed]
 
Lader M: Recent experience with trazodone. Psychopathology 20 (suppl 1):39–47, 1987
 
Lance R, Albo M, Costabile RA, et al: Oral trazodone as empirical therapy for erectile dysfunction: a retrospective review. Urology 46:117–120, 1995
[PubMed]
 
Landen M, Ericksson O, Sundblad C, et al: Compounds with affinity for serotonergic receptors in the treatment of premenstrual dysphoria: a comparison of buspirone, nefazodone and placebo. Psychopharmacology (Berl) 155:292–298, 2001
[PubMed]
 
Laroudie C, Salazar DE, Cosson JP, et al: Carbamazepine–nefazodone interaction in healthy subjects. J Clin Psychopharmacol 20:46–53, 2000
[PubMed]
 
Lippman S, Bedford P, Manshadi M, et al: Trazodone cardiotoxicity (letter). Am J Psychiatry 140:1383, 1983
 
Lucena MI, Andrade RJ, Gomez-Outes A, et al: Acute liver failure after treatment with nefazodone. Dig Dis Sci 44:2577–2579, 1999
[PubMed]
 
Maes M, Westenberg H, Vandoolaeghe E, et al: Effects of trazodone and fluoxetine in the treatment of major depression: therapeutic pharmacokinetic and pharmacodynamic interactions through formation of meta-chlorophenylpiperazine. J Clin Psychopharmacol 17:358–364, 1997
[PubMed]
 
Margolese HC, Chouinard G: Serotonin syndrome from the addition of low-dose trazodone to nefazodone. Am J Psychiatry 157:1022, 2000
[PubMed]
 
Martinon-Torres G, Fioravanti M, Grimley EJ: Trazodone for agitation in dementia. Cochrane Database Syst Rev (4):CD004990, 2004
 
Mayol RF, Cole CA, Luke GM, et al: Characterization of the metabolites of the antidepressant drug nefazodone in human urine and plasma. Drug Metab Dispos 22:304–311, 1994
[PubMed]
 
Mendelson WB: A review of the evidence for the efficacy and safety of trazodone in insomnia. J Clin Psychiatry 66:469–476, 2005
[PubMed]
 
Montejo AL, Llorca G, Izquierdo JA, et al: Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. J Clin Psychiatry 62 (suppl 3):10–21, 2001
 
Monteleone P, Gnocchi G: Evidence for a linear relationship between plasma trazodone levels and clinical response in depression in the elderly. Clin Neuropharmacol 13 (suppl 1):84–89, 1990
 
Nacca A, Guiso G, Fracasso C, et al: Brain-to-blood partition and in vivo inhibition of 5-hydroxytryptamine reuptake and quipazine-mediated behaviour of nefazodone and its main active metabolites in rodents. Br J Pharmacol 125:1617–1623, 1998
[PubMed]
 
Nambudiri DE, Mirchandani IC, Young RC: Two more cases of trazodone-related syncope in the elderly. J Geriatr Psychiatry Neurol 2:225, 1989
[PubMed]
 
Narayan M, Anderson G, Cellar J, et al: Serotonin transporter-blocking properties of nefazodone assessed by measurement of platelet serotonin. J Clin Psychopharmacol 18:67–71, 1998
[PubMed]
 
Nierenberg A, Adler LA, Peselow E, et al: Trazodone for antidepressant-associated insomnia. Am J Psychiatry 151:1069–1072, 1994
[PubMed]
 
Nisijima K, Shimizu M, Abe T, et al: A case of serotonin syndrome induced by concomitant treatment with low-dose trazodone and amitriptyline and lithium. Int Clin Psychopharmacol 11:289–290, 1996
[PubMed]
 
Passos SR, Camacho LA, Lopes CS, et al: Nefazodone in out-patient treatment of inhaled cocaine dependence: a randomized double-blind placebo-controlled trial. Addiction 100:489–494, 2005
[PubMed]
 
Pazzagli M, Giovannini MG, Pepeu G: Trazodone increases extracellular serotonin levels in the frontal cortex of rats. Eur J Pharmacol 383:249–257, 1999
[PubMed]
 
Pescatori ES, Engelman JC, Davis G, et al: Priapism of the clitoris: a case report following trazodone use. J Urol 149:1557–1559, 1993
[PubMed]
 
Pigott TA, Leheureux F, Rubenstein CS, et al: A double-blind, placebo-controlled study of trazodone in patients with obsessive-compulsive disorder. J Clin Psychopharmacol 12:156–162, 1992
[PubMed]
 
Poon IO, Braun U: High prevalence of orthostatic hypotension and its correlation with potentially causative medications among elderly veterans. J Clin Ther 30:173–178, 2005
[PubMed]
 
Preskorn SH: Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry 56 (suppl):12–21, 1995
 
Purcell P, Ghurye R: Trazodone and spontaneous orgasms in an elderly postmenopausal woman: a case report. J Clin Psychopharmacol 15:293–295, 1995
[PubMed]
 
Razavi D, Kormoss N, Collard A, et al: Comparative study of the efficacy and safety of trazodone versus clorazepate in the treatment of adjustment disorders in cancer patients: a pilot study. J Int Med Res 27:264–272, 1999
[PubMed]
 
Reeves RR, Bullen JA: Serotonin syndrome produced by paroxetine and low-dose trazodone. Psychosomatics 36:159–160, 1995
[PubMed]
 
Rickels K, Downing R, Schweizer E, et al: Antidepressants for the treatment of generalized anxiety disorder: a placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry 50:884–895, 1993
[PubMed]
 
Rickels K, Robinson DS, Schweizer E, et al: Nefazodone: aspects of efficacy. J Clin Psychiatry 56 (suppl 6):43–46, 1995
 
Robinson DS, Roberts DL, Smith JM, et al: The safety profile of nefazodone. J Clin Psychiatry 57 (suppl 2):31–38, 1996
 
Rosenberg RP: Sleep maintenance insomnia: strengths and weaknesses of current pharmacologic therapies. Ann Clin Psychiatry 18:49–56, 2006
[PubMed]
 
Rotzinger S, Fang J, Baker GB: Trazodone is metabolized to m-chlorophenylpiperazine by CYP3A4 from human sources. Drug Metab Dispos 26:572–575, 1998
[PubMed]
 
Roy-Byrne PP, Pages KP, Russo JE, et al: Nefazodone treatment of major depression in alcohol-dependent patients: a double-blind, placebo-controlled trial. J Clin Psychopharmacol 20:129–136, 2000
[PubMed]
 
Saper JR, Lake AE, Tepper SJ: Nefazodone for chronic daily headache prophylaxis: an open-label study. Headache 41:465–474, 2001
[PubMed]
 
Schatzberg AF: Trazodone: a 5-year review of antidepressant efficacy. Psychopathology 20 (suppl 1):48–56, 1987
 
Schatzberg AF, Rush AJ, Arnow BA, et al: Chronic depression: medication (nefazodone) or psychotherapy (CBASP) is effective when the other is not. Arch Gen Psychiatry 62:513–520, 2005
[PubMed]
 
Schirren CA, Baretton G: Nefazodone-induced acute liver failure. Am J Gastroenterol 95:1596–1597, 2000
[PubMed]
 
Serzone (package insert). Princeton, NJ, Bristol-Myers Squibb, February 2002
 
Sharpley AL, Williamson DJ, Attenburrow ME, et al: The effects of paroxetine and nefazodone on sleep: a placebo controlled trial. Psychopharmacology (Berl) 126:50–54, 1996
[PubMed]
 
Shen J, Kennedy SH, Levitan RD, et al: The effects of nefazodone on women with seasonal affective disorder: clinical and polysomnographic analyses. J Psychiatry Neurosci 30:11–16, 2005
[PubMed]
 
Shopsin B, Cassano GB, Conti L: An overview of new "second generation" antidepressant compounds: research and treatment implications, in Antidepressants: Neurochemical, Behavioral and Clinical Perspectives. Edited by Enna SJ, Molick J, Richelson E. New York, Raven, 1981, pp 219–251
 
Silvestrini G: Introductory remarks on trazodone and its position in treatment of psychiatric diseases, in Trazodone: A New Broad-Spectrum Antidepressant (Proceedings of the Symposium of the 11th Congress of the Collegium Internationale Neuro-Psychopharmacologicum, Vienna 1978). Edited by Gershon ES, Rickels K, Silvestrini G. Amsterdam, Excerpta Medica, 1980, pp 34–38
 
Small NL, Giamonna KA: Interaction between warfarin and trazodone. Ann Pharmacother 34:734–736, 2000
[PubMed]
 
Spar JE: Plasma trazodone concentrations in elderly depressed inpatients: cardiac effects and short-term efficacy. J Clin Psychopharmacol 7:406–409, 1987
[PubMed]
 
Sulser F: Mode of action of antidepressant drugs. J Clin Psychiatry 44 (5 pt 2):14–20, 1983
 
Sultzer DL, Gray KF, Gunay I, et al: A double-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia. Am J Geriatr Psychiatry 5:60–69, 1997
[PubMed]
 
Taylor DP, Smith DW, Hyslop DK, et al: Receptor binding and atypical antidepressant drug discovery, in Receptor Binding in Drug Research. Edited by O'Brien RA. New York, Marcel Dekker, 1986, pp 151–165
 
Terao T: Comparison of manic switch onset during fluoxetine and trazodone treatment. Biol Psychiatry 33:477–478, 1993
[PubMed]
 
Teri L, Logsdon RG, Peskind E, et al: Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. Neurology 55:1271–1278, 2001
 
Thapa PB, Gideon P, Cost TW, et al: Antidepressants and the risk of falls among nursing home residents. N Engl J Med 339:875–882, 1998
[PubMed]
 
Thompson JW Jr, Ware MR, Blashfield RK: Psychotropic medication and priapism: a comprehensive review. J Clin Psychiatry 51:430–433, 1990
[PubMed]
 
van Ameringen M, Mancini C, Oakman J, et al: Nefazodone in the treatment of generalized social phobia: a randomized, placebo-controlled trial. J Clin Psychiatry 68:288–295, 2007
 
van Moffaert M, de Wilde J, Vereecken A, et al: Mirtazapine is more effective than trazodone: a double-blind controlled study in hospitalized patients with major depression. Int Clin Psychopharmacol 10:3–9, 1995
 
Warner MD, Dorn MR, Peabody CA: Survey on the usefulness of trazodone in patients with PTSD with insomnia or nightmares. Pharmacopsychiatry 34:128–131, 2001
[PubMed]
 
Weisler RH, Johnston JA, Lineberry CG, et al: Comparison of bupropion and trazodone for the treatment of major depression. J Clin Psychopharmacol 14:170–179, 1994
[PubMed]
 
Wetzel H, Szegedi A, Scheurich A, et al: Combination treatment with nefazodone and cognitive-behavioral therapy for relapse prevention in alcohol-dependent men: a randomized controlled study. J Clin psychiatry 65:1406–1413, 2004
[PubMed]
 
Winkler D, Ortner R, Pjrek E, et al: Trazodone-induced cardiac arrhythmias: a report of two cases. Hum Psychopharm Clin Exp 21:61–62, 2006
[PubMed]
 
Worthington JJ 3rd, Zucker BG, Fones CS, et al: Nefazodone for social phobia: a clinical case series. Depress Anxiety 8:131–133, 1998
[PubMed]
 
Wright DH, Lake KD, Bruhn PH, et al: Nefazodone and cyclosporine drug-drug interaction. J Heart Lung Transplant 18:913–915, 1999
[PubMed]
 
Zajecka J, McEnany GW, Lusk KM: Antidepressant dosing and switching guidelines: focus on nefazodone. J Clin Psychiatry 63:42–47, 2002
[PubMed]
 
Zalma A, von Moltke LL, Granda BW, et al: In vitro metabolism of trazodone by CYP3A: inhibition by ketoconazole and human immunodeficiency viral protease inhibitors. Biol Psychiatry 47:655–661, 2000
[PubMed]
 
Zimmer B, Daly F, Benjamin L: More on combination antidepressant therapy. Arch Gen Psychiatry 41:527–528, 1984
[PubMed]
 
+

CME Activity

Add a subscription to complete this activity and earn CME credit.
Sample questions:
1.
In regard to pharmacological profile, trazodone may be best described as
2.
You start your patient, a 72-year-old man, on trazodone, advising him to take the medication at bedtime. He calls you the next day to tell you that he was light-headed and dizzy and almost fell when he got out of bed that morning. Knowing the pharmacological profile of trazodone, you attribute this side effect to which of the following properties of the drug?
3.
A relatively rare (1 in 6,000) but dramatic side effect associated with trazodone is
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Related Content
Articles
Books
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 3.  >
The American Psychiatric Publishing Textbook of Psychiatry, 5th Edition > Chapter 26.  >
Gabbard's Treatments of Psychiatric Disorders, 4th Edition > Chapter 23.  >
Helping Parents, Youth, and Teachers Understand Medications for Behavioral and Emotional Problems: A Resource Book of Medication Information Handouts, 3rd Edition > Chapter 57.  >
Dulcan's Textbook of Child and Adolescent Psychiatry > Chapter 47.  >
Topic Collections
Psychiatric News
PubMed Articles
Liver injury associated with antidepressants. Curr Drug Saf 2013;8(3):207-23.
Antidepressant-induced liver injury: a review for clinicians. Am J Psychiatry 2014;171(4):404-15.doi:10.1176/appi.ajp.2013.13050709.
 
  • Print
  • PDF
  • E-mail
  • Chapter Alerts
  • Get Citation